Clinically, the ATTAIN Phase 3 program showed that orforglipron at its highest dose delivered a mean weight loss of 12.4% over 72 weeks, slightly less than the WEGOVY pills 13.6% at 64 weeks, but with a broader, more diverse patient population of over 3,000 participants
This percentage provides effective results while minimising the risk of irritation
Future studies are required to gain a better understanding of the intestinal conditions that might influence butyrate production in individuals with T2D, in relation both to the diet and the individualized gut microbiota
Researchers later began combining these two compounds in controlled environments to observe potential additive or synergistic effects on recovery and cellular restoration
While semaglutide is effective for weight loss, some people may experience side effects, particularly in the first few weeks of treatment
It is only very difficult now to get enough of the drug to do the studies due to its unprecedented popularity